Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label study of pazopanib eye drops in age-related macular degeneration
2011-000243-24Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in age-related macular degeneration (AMD), sponsored by GSK. Primary endpoints: Change from baseline in central retinal thickness and Change from baseline in best-corrected visual acuity (BCVA). Started Apr 2011; status: completed.
02
Drugs
pazopanib
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2011-000243-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000243-24.